NASDAQ$ACHC

Acadia Healthcare Company Inc. · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Acadia Healthcare reported strong financial results driven by the execution of its growth strategy and commitment to providing quality care.

Acadia Healthcare reported an 8.7% increase in revenue, totaling $815.6 million for Q3 2024. Net income attributable to Acadia was $68.1 million, or $0.74 per diluted share, while adjusted income was $84.1 million, or $0.91 per diluted share. The company is on track to expand its facilities and bed capacity.

  • Revenue totaled $815.6 million, an increase of 8.7% over the third quarter of 2023.
  • Same facility revenue increased 8.6% compared with the third quarter of 2023, including an increase in revenue per patient day of 3.6% and an increase in patient days of 4.7%.
  • Net income attributable to Acadia totaled $68.1 million, or $0.74 per diluted share.
  • Adjusted income attributable to Acadia totaled $84.1 million, or $0.91 per diluted share.

Headline financials

Total Revenue

$816M

Previous: $750M+8.7%
EPS

$0.74

Previous: $0.91-18.7%
US Same-Facility Rev. Growth

8.6%

Previous: 13.0%-33.8%
US Same-Facility Patient Days Growth

4.7%

Previous: 6.0%-21.7%
US Same-Facility Rev/Day Growth

3.6%

Previous: 6.6%-45.5%
Capital Expenditures

-$487M

Previous: -$285M-70.6%
Free Cash Flow

-$419M

Previous: -$503M+16.8%
Net Income

$68.1M

Previous: -$218M+131.3%
Operating Income

-$134M

Previous: -$149M+9.7%
Cash & Equivalents

$82.1M

Previous: $99.6M-17.5%
Total Assets

$5.87B

Previous: $5.35B+9.8%
Stock-Based Comp

$9.47M

Previous: $8.16M+16.0%

Revenue & EPS history

Acadia Healthcare · Revenue · Quarterly

$816M

Q3 2024+8.7%vs Q3 2023
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Forward guidance

Acadia revised its financial guidance for 2024, anticipating revenue between $3.150 to $3.165 billion and adjusted earnings per diluted share between $3.35 and $3.45.

Tailwinds

  • Revenue between $3.150 to $3.165 billion.
  • Adjusted EBITDA between $725 to $735 million.
  • Adjusted earnings per diluted share between $3.35 to $3.45.
  • Operating cash flows $525 to $550 million
  • Total bed additions, excluding acquisitions approximately 1,200 beds

Headwinds

  • Interest expense $110 to $120 million
  • Tax rate not specified
  • Depreciation and amortization expense $145 to $155 million.
  • Stock compensation expense $40 to $45 million.
  • Expansion capital expenditures $550 to $595 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

+1.5%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+2.5%

Avg return

30 days after

60%

38 / 63 earnings

Positive

+23.1%

Q3 2020

Best reaction

-26.9%

Q3 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.5%+0.3%-16.0%
Q4 2025+21.4%+36.5%+33.4%
Q3 2025-5.5%-10.2%-25.2%
Q1 2025+4.2%+1.2%-14.4%
Q4 2024-25.5%-26.3%-25.2%
Q3 2024-17.3%-18.0%-21.3%
Q2 2024+10.0%+5.4%+21.6%
Q1 2024-9.8%-8.3%-6.8%
Q4 2023-2.4%-1.8%-7.3%
Q3 2023-1.7%+1.1%+0.5%
Q2 2023+7.8%+6.5%+2.9%
Q1 2023-1.3%-4.4%-6.0%
Q4 2022-9.6%-7.3%-12.1%
Q3 2022-3.4%-5.5%+7.2%
Q2 2022+3.6%+3.9%+4.8%
Q1 2022+8.0%+5.4%+6.4%
Q4 2021+6.5%+9.3%+15.3%
Q3 2021+10.5%+11.8%+3.0%
Q2 2021+3.1%+1.3%+8.0%
Q1 2021-1.1%+1.1%+4.4%
Q4 2020+1.5%+2.5%+6.0%
Q3 2020+23.1%+28.7%+49.1%
Q2 2020+2.3%+2.7%-0.1%
Q1 2020+16.7%+18.2%+26.7%
Q4 2019-5.9%+6.0%+100.5%
Q3 2019-3.5%-2.0%+2.5%
Q2 2019-3.3%-12.0%-19.6%
Q1 2019+0.0%+3.2%+1.4%
Q4 2018+15.9%+11.7%+11.7%
Q3 2018-12.8%-5.0%-26.0%
Q2 2018-10.6%-7.4%-8.0%
Q1 2018+9.0%+11.7%+13.0%
Q4 2017+8.5%+6.8%+8.4%
Q3 2017-26.9%-25.6%-30.7%
Q2 2017+7.6%+5.7%-7.5%
Q1 2017-3.1%+0.0%-2.4%
Q4 2016+5.4%+4.9%-1.7%
Q3 2016+3.1%+3.8%+5.9%
Q2 2016-1.3%-0.8%-4.8%
Q1 2016-0.8%
Q4 2015+5.7%
Q3 2015+9.4%
Q2 2015+3.4%
Q1 2015-2.9%
Q4 2014-0.4%
Q3 2014+11.2%
Q2 2014-2.1%
Q1 2014+0.4%
Q4 2013-2.8%
Q3 2013+9.0%
Q2 2013+8.2%
Q1 2013+2.9%
Q4 2009+2.3%
Q4 2012+0.1%
Q3 2012+2.3%
Q2 2012+7.5%
Q2 2011+4.4%
Q1 2012+6.5%
Q1 2011-1.0%
Q4 2011+3.3%
Q4 2010+0.1%
Q3 2011+0.1%
Q3 2010+0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro